Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Jun 30, 2025	Dec 31, 2024
Selling, General & Admin	19.26	14.25
Research & Development	101.16	81.01
Operating Expenses	120.42	95.26
Operating Income	-120.42	-95.26
Interest Expense	-0.64	-1.6
Interest & Investment Income	14.34	6.4
Other Non Operating Income (Expenses)	-0	0
EBT Excluding Unusual Items	-106.72	-90.46
Other Unusual Items	-0.87	-0.87
Pretax Income	-107.59	-91.34
Net Income	-107.59	-91.34
Preferred Dividends & Other Adjustments	-30.15	-20.39
Net Income to Common	-77.43	-70.95
Shares Outstanding (Basic)	36	17
Shares Outstanding (Diluted)	36	17
EPS (Basic)	-2.14	-4.23
EPS (Diluted)	-2.14	-4.23
Free Cash Flow	-96.16	-63.3
Free Cash Flow Per Share	-2.66	-3.77
EBITDA	-	-95.23
D&A For EBITDA	-	0.03
EBIT	-120.42	-95.26

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q